YewMaker’s new research has found a strong public support for transparency and action on the carbon emissions of medicines. The survey, conducted across the UK, US, Australia and France, revealed that 84% of respondents want medicine manufacturers to disclose the carbon footprint of their products and 84% wish healthcare to actively reduce the carbon emissions of medicines.
Nazneen Rahman, CEO at YewMaker, commented: “This research demonstrates a strong public desire for the NHS and pharmaceutical companies to measure and mitigate the carbon footprint of medicines, which account for a large proportion of NHS emissions. YewMaker is developing MCF Classifier to provide standardised carbon footprints for thousands of medicines, equipping healthcare professionals with the knowledge they need to make carbon-informed decisions about medicines.”
The research uncovered a preference among individuals for information on medicines they could buy themselves compared with medicines prescribed for them, as they felt it could empower them to make environmentally conscious decisions.
MCF Classifier is supported by SBRI Healthcare and the Greener NHS and harnesses data science and green chemistry prediction metrics to calculate the carbon emissions per dose for over 2,000 medicines. These emissions are categorised into four MCF Ratings, facilitating comparisons and benchmarking. YewMaker is set to launch the MCF Formulary, a user-friendly web application, in early 2024, making the MCF Ratings accessible to all.
A study conducted by YewMaker has revealed strong public support for transparency and action on the carbon emissions of medicines. The survey, which was conducted in four countries, showed that 84% of respondents wanted medicine manufacturers to disclose the carbon footprint of their products and 84% wanted healthcare to actively reduce the carbon emissions of medicines.
Nazneen Rahman, CEO at YewMaker, said: “This research demonstrates a strong public desire for the NHS and pharmaceutical companies to measure and mitigate the carbon footprint of medicines, which account for a large proportion of NHS emissions.”
The survey uncovered a preference among individuals for information on medicines they could buy themselves, as they felt it could empower them to make environmentally conscious decisions. YewMaker is developing MCF Classifier, a system which provides standardised carbon footprints for thousands of medicines. MCF Classifier harnesses data science and green chemistry prediction metrics to calculate the carbon emissions per dose for over 2,000 medicines and categorise them into four MCF Ratings. YewMaker are set to launch the MCF Formulary, a user-friendly web application, in early 2024.
New research from YewMaker has revealed a strong public support for transparency and action on the carbon emissions of medicines. The survey, conducted across the UK, US, Australia and France, found that 84% of respondents wanted medicine manufacturers to disclose the carbon footprint of their products and 84% wanted healthcare to actively reduce the carbon emissions of medicines.
Nazneen Rahman, CEO at YewMaker, commented: “This research demonstrates a strong public desire for the NHS and pharmaceutical companies to measure and mitigate the carbon footprint of medicines, which account for a large proportion of NHS emissions.”
The survey also showed that individuals preferred to receive information about the carbon footprint of the medicines they consume, demonstrating a growing interest in making informed choices. YewMaker is developing MCF Classifier, a system which provides standardised carbon footprints for thousands of medicines. MCF Classifier harnesses data science and green chemistry prediction metrics to calculate the carbon emissions per dose for over 2,000 medicines and categorise them into four MCF Ratings. YewMaker are set to launch the MCF Formulary, a user-friendly web application, in early 2024.
A new study by YewMaker has found a strong public support for transparency and action on the carbon emissions of medicines. The survey, conducted across the UK, US, Australia and France, revealed that 84% of respondents want medicine manufacturers to disclose the carbon footprint of their products and 84% want healthcare to actively reduce the carbon emissions of medicines.
Nazneen Rahman, CEO at YewMaker, said: “This research demonstrates a strong public desire for the NHS and pharmaceutical companies to measure and mitigate the carbon footprint of medicines, which account for a large proportion of NHS emissions. YewMaker is developing MCF Classifier to provide standardised carbon footprints for thousands of medicines, equipping healthcare professionals with the knowledge they need to make carbon-informed decisions about medicines.”
The survey also found that 73% of respondents consider it important for doctors to have access to carbon footprint information when prescribing medicines and 53% of participants personally wish to receive information about the carbon footprint of the medicines they consume. YewMaker’s MCF Classifier harnesses data science and green chemistry prediction metrics to calculate the carbon emissions per dose for over 2,000 medicines and categorise them into four MCF Ratings. YewMaker are set
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.